Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROP2 CAR-NK Cells and Belzutifan in Pancreatic Cancer
NCT07377526Phase 2Suspended
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2026
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TROP2 CAR/IL-15 TGFBR2 KO NK cells in pancreatic cancer (PC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Adverse Events at 1 year and Dose-Limiting Toxicity at 1 year. Started May 2026; status: suspended.
02
Drugs
TROP2 CAR/IL-15 TGFBR2 KO NK cells
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07377526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377526.